HDAC9 and melanoma: The HDAC inhibitors vorinostat and valproic acid (VPA) decrease the migration potential of BRAFV600E mutant melanoma cells by increasing the expression of plasma membrane Ca2+ ATPase 4b (PMCA4b) (Hegedus et al., 2017).